Prefer to view this content on our website? Click here.
Dear Fellow Investor,
A New Multi-Billion-Dollar Healthcare Revolution Is Already Here
The artificial intelligence (AI) boom isn’t just transforming tech—it’s reshaping healthcare at a breakneck pace.
In fact, the healthcare AI market is projected to skyrocket from $11 billion in 2021 to $187 billion by 2030, according to Statista. That’s more than a 1,600% increase in less than a decade.
What’s driving this exponential growth?
The use of AI in diagnostics, genomics, precision medicine, pharmaceutical R&D, imaging analysis, and digital health infrastructure is unlocking efficiency and innovation we’ve never seen before. It’s not just a trend—it’s the foundation of healthcare’s future.
And smart investors are already positioning themselves to benefit.
The AI-Healthcare Convergence Is Creating a Massive Opportunity
Artificial intelligence is reshaping the entire healthcare ecosystem—faster diagnostics, personalized treatment plans, smarter R&D, and predictive analytics for better patient outcomes. The potential to cut costs, save lives, and improve efficiencies is drawing attention from both Big Tech and Big Pharma.
Let’s take a look at four companies already making big moves in healthcare AI:
Company: Bio-Techne Corporation (SYM: TECH)
Bio-Techne is leading the charge in AI-driven cellular therapy research.
The company recently launched a new suite of AI-designed recombinant proteins. These proteins are engineered to address critical challenges in cell therapy workflows and research applications—such as improving cell culture performance and enabling optimized cell expansion.
As regenerative medicine and cellular therapies take off, Bio-Techne's AI-powered approach positions it as a major player in next-gen biotech.
Company: BioNTech (SYM: BNTX)
You might remember BioNTech as a key player in COVID-19 vaccine development, but the company is now using AI to go far beyond the pandemic.
Partnering with its in-house AI arm, InstaDeep, BioNTech is developing personalized cancer vaccines and immunotherapies. By using AI to analyze individual genetic profiles, the company aims to create truly customized treatments—something that would have been unthinkable just a few years ago.
This AI-first approach to individualized medicine is potentially game-changing in oncology and beyond.
Trade Algo
Get Our TradeGPT Insight Alerts For FREE To Instantly Gain An Unfair Advantage In The Stock Market
TradeGPT is a revolutionary new technology that uses LLM and artificial intelligence to unlock AI-powered insights for options trades...
...this allows you to make smart, data-driven trading decisions with ease.
👉 Click Here To Claim Your FREE TradeGPT Alerts
Company: Recursion Pharmaceuticals (SYM: RXRX)
Recursion is a standout in what’s being called “TechBio”—the merger of AI and biotech to revolutionize drug discovery.
The company recently released Boltz-2, an open-source AI model developed in collaboration with MIT. This biomolecular foundation model is expected to drastically accelerate drug development, reduce R&D costs, and enhance success rates.
Recursion’s use of machine learning, imaging, and vast datasets to decode biology is quickly earning it recognition as a pioneer in AI-powered pharma.
Company: Avantor Inc. (SYM: AVTR)
Avantor is using AI to create the Lab of the Future.
By integrating AI into its laboratory workflows and supply chain operations, Avantor is driving gains in efficiency, accuracy, and automation. The company provides essential products and services to the biotech, pharmaceutical, and medical research industries—so its AI improvements have an impact across the entire healthcare landscape.
True Market Insiders
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
While $51 million is basically chump change to Elon Musk…
It’s just the beginning…
He’s planning to invest a lot more.
Because this “Miracle Metal” is not only 400 times stronger than steel… Weighs 85% less… It conducts electricity better than copper… And its heat conductivity surpasses even diamonds…
But it’s poised to solve a $267 billion flaw threatening artificial intelligence as a whole… and could stop development in its tracks…
This is the most exciting opportunity that’s come across my desk in a while… since I recommended Tesla more than 12 years ago…
I reveal all of the details here.
Don’t Want to Pick Stocks? Use These Healthcare AI ETFs Instead
If you're looking to play the booming healthcare AI trend but want instant diversification, thematic ETFs offer a powerful and lower-risk way to get broad exposure.
Here are three to consider:
ETF: HealthTech ETF (SYM: HEAL)
-
Expense Ratio: 0.50%
-
Focus: Companies transforming healthcare through tech—especially AI
-
Themes: Drug discovery, smart medical devices, analytics, and consumer health tech
-
Top Holdings: Tempus AI, Hims & Hers Health, ResMed, Dexcom, Insulet
This ETF is a direct play on the AI + healthcare convergence, offering exposure to both established names and emerging disruptors.
ETF: Vanguard Health Care ETF (SYM: VHT) -
Expense Ratio: 0.09%
-
Focus: Broad healthcare sector exposure including medtech, biotech, and services
-
Dividend Yield: Quarterly payouts (last two were $0.94 and $0.96 per share)
While not an AI-exclusive ETF, VHT includes many healthcare leaders now adopting AI in their business models. It’s a good long-term core holding with consistent income and growth.
ETF: Artificial Intelligence & Technology ETF (SYM: AIQ)
-
Expense Ratio: 0.68%
-
Focus: Global leaders in AI and digital transformation
-
Top Holdings: Nvidia, Microsoft, Oracle, Palantir, Broadcom
Though broader in focus, AIQ gives you exposure to the backbone of AI innovation—including the chipmakers and software platforms enabling healthcare AI’s rise.
Crypto 101
The Policy Behind Trump’s Crypto Boom
Crypto isn’t just recovering…It’s surging, BIG TIME!
Bitcoin recently hit all-time highs, and a powerful new force is emerging: Trump’s crypto blueprint in action.
This is no coincidence.
What many miss is that this administration is laying the groundwork for the next phase of growth…
Trump’s top-level appointments are setting a pro-crypto agenda.
Clearing regulatory hurdles that have historically slowed innovation.
Institution-level crypto reserves are being quietly secured, signaling a broader move toward long-term adoption.
Now we’re seeing a crypto market that’s breaking records (by design!).
That’s why we put together an urgent, actionable blueprint that maps out everything you need to know.
Click here to access my urgent blueprint now →
Are there any other AI or healthcare stocks you've got your eye on? Which ones? What particular sectors of the market are you buying right now? Hit "reply" to this email and let us know your thoughts!
